AstraZeneca (AZN) Earns “Overweight” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their overweight rating on shares of AstraZeneca (LON:AZN) in a report issued on Friday, October 19th. They currently have a GBX 6,500 ($84.93) price objective on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the stock. Shore Capital restated a hold rating on shares of AstraZeneca in a report on Tuesday, July 24th. Deutsche Bank reiterated a buy rating and set a GBX 6,000 ($78.40) price target on shares of AstraZeneca in a research note on Friday, July 27th. Liberum Capital reiterated a hold rating on shares of AstraZeneca in a research note on Monday, September 24th. Jefferies Financial Group boosted their price target on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 6,050 ($79.05) and gave the stock a buy rating in a research note on Friday, July 13th. Finally, UBS Group reiterated a neutral rating and set a GBX 5,600 ($73.17) price target on shares of AstraZeneca in a research note on Monday, July 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Hold and an average price target of GBX 5,831.89 ($76.20).

Shares of LON AZN traded up GBX 79 ($1.03) during trading on Friday, hitting GBX 6,172 ($80.65). 2,861,442 shares of the company were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a 12-month low of GBX 4,260 ($55.66) and a 12-month high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: What is Cost of Capital?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply